1. Home
  2. MMS vs PBLS Comparison

MMS vs PBLS Comparison

Compare MMS & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maximus Inc.

MMS

Maximus Inc.

HOLD

Current Price

$58.53

Market Cap

3.2B

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$40.40

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MMS
PBLS
Founded
1975
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.6B
IPO Year
1997
2026

Fundamental Metrics

Financial Performance
Metric
MMS
PBLS
Price
$58.53
$40.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
547.4K
333.6K
Earning Date
05-07-2026
N/A
Dividend Yield
2.02%
N/A
EPS Growth
10.42
N/A
EPS
5.45
N/A
Revenue
$2,392,236,000.00
N/A
Revenue This Year
$0.44
N/A
Revenue Next Year
$5.15
N/A
P/E Ratio
$10.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$52.73
$25.56
52 Week High
$100.00
$41.49

Technical Indicators

Market Signals
Indicator
MMS
PBLS
Relative Strength Index (RSI) 51.35 63.79
Support Level $58.26 $37.88
Resistance Level $63.44 $41.49
Average True Range (ATR) 1.42 2.18
MACD 0.09 -0.18
Stochastic Oscillator 66.26 71.48

Price Performance

Historical Comparison
MMS
PBLS

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: